Gender-affirming hormone therapy reduces depression and anxiety in trans and non-binary youth

24 Jan 2023 • Published on the 23rd of January, 2023.

The study demonstrates that gender-affirming hormone (GAH) treatment is valuable for transgender and nonbinary adolescents—a group at an elevated risk of suicidality, depression, and anxiety.

The study, from July 2016 through June 2019, included 315 transgender and nonbinary young people 12 to 20 years of age.

The new study further validates the struggles so many trans youth face on a daily basis, which partially revolves around fitting in, feeling comfortable in their own skin, and being happy in their everyday life.

When a person’s body and appearance conflict with their gender identity, they may experience “gender dysphoria.” It is well-documented that such dysphoria is associated with higher rates of unwanted psychological outcomes such as suicide, depression, anxiety, substance use, emotional dysregulation, and others.

Bringing a person’s physical characteristics in line with their gender identity is referred to as “gender congruence.” The new study found that achieving gender congruence was associated with reductions in depression and anxiety symptoms.

Source: Medical News Today | Read full story

Contact us

support@medflix.app

+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd

InstagramFacebookTwitter